Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
There are studies that suggest glycemic response to incretin-based therapies differs between
Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the
therapeutic response could also be augmented by difference in incretin system among various
ethnicities. This study is carried out to study the effect of dipeptidyl-peptidase IV (DPPIV)
inhibitors in prediabetes and T2DM patients who have different levels of GLP-1 and to
determine the effect on glycemic profiles, insulin resistance/sensitivity, beta-cell functon.